Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE AND ACETIC ACID versus TRIACIN C.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE AND ACETIC ACID versus TRIACIN C.
HYDROCORTISONE AND ACETIC ACID vs TRIACIN-C
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone is a corticosteroid that binds to the glucocorticoid receptor, leading to increased lipocortin synthesis, inhibition of phospholipase A2, decreased arachidonic acid release, and reduced prostaglandin and leukotriene production; it also suppresses cytokine expression and immune cell migration. Acetic acid is a weak acid that lowers local pH, inhibiting bacterial and fungal growth and disrupting microbial cell membranes.
TRIACIN-C is a combination of triamcinolone (a corticosteroid) and nystatin (an antifungal). Triamcinolone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Nystatin binds to ergosterol in fungal cell membranes, causing pore formation and cell death.
Instill 5 drops into affected ear(s) twice daily for 7-10 days; or as directed by physician.
5 mg orally twice daily, taken with meals to enhance absorption.
None Documented
None Documented
Plasma t1/2: 1.5-2 hours; biological t1/2: 8-12 hours (based on HPA axis suppression).
Terminal elimination half-life: 7–9 hours. In patients with severe hepatic impairment (Child-Pugh C), half-life may extend to 15 hours; dosing adjustment recommended.
Renal: ~60-70% as metabolites; biliary/fecal: ~10-15%; unchanged drug: <5%.
Renal: ~60% as unchanged drug; hepatic metabolism accounts for ~25% (primarily via CYP3A4), with biliary excretion of metabolites (~15%); fecal elimination <5%.
Category D/X
Category C
Corticosteroid
Corticosteroid